AI summary · may contain errors
A cohort study of clinically diagnosed pernio characterizes patients’ clinical presentation, etiologic associations, and treatment outcomes.
- Open access
American Medical Association · Clinical Medicine · ISSN 2168-6068, 2168-6084
Rebuilt
Newest first · last 60 days
AI summary · may contain errors
A cohort study of clinically diagnosed pernio characterizes patients’ clinical presentation, etiologic associations, and treatment outcomes.
AI summary · may contain errors
Clinical Insights summarizes how to recognize autoinflammatory diseases in dermatology by outlining their clinical features, diagnostic approaches, and therapeutic strategies.
AI summary · may contain errors
Morphea and systemic sclerosis are linked to higher overall cancer incidence than the general population, with SIRs of 1.24 and 1.37, respectively.
AI summary · may contain errors
Two patients with tuberculosis verrucosa cutis complicated by chronic lymphedema were diagnosed using targeted next-generation sequencing.
AI summary · may contain errors
In a quota-based online survey of 10 636 US adults, self-reported health care professional-diagnosed chronic hand eczema had a prevalence of 9.6% (95% CI, 9.0%-10.2%).
AI summary · may contain errors
A teenaged girl with lifelong, progressive diffuse lip swelling of both lips and a lower eyelid margin nodule suggests a congenital or early-onset granulomatous disorder.
AI summary · may contain errors
Brepocitinib in adults with biopsy-proven active cutaneous sarcoidosis improved CSAMI-A scores by 22.3 points (45 mg) and 22.2 points (15 mg) at week 16 versus 0.7 with placebo (P < .001).
AI summary · may contain errors
A woman in her 70s with a 3-year history of extensive coral treelike telangiectasias on the trunk and lower limbs is described after prior diffuse large B-cell lymphoma of the right breast diagnosis.
AI summary · may contain errors
Nemolizumab is assessed for effectiveness and safety in patients with severe pruritus associated with cutaneous T-cell lymphoma.
AI summary · may contain errors
In a French single-center cohort of hidradenitis suppurativa patients with partial biologic response, an end-of-dose effect–guided strategy was linked to IHS4 improvement, with 53.8% achieving ≥3-point response at 3–5 months.
Journals this month
Topics moving, week to 17 Nov 2026
By field